ConductScience.org, home

Paper36966213

Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy.

Ramdial J and 5 others. Bone Marrow Transplant, 2023. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy. Papers, record 36966213. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36966213

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy.
PubMed
Journal
Bone Marrow Transplant
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Relative citation ratio, by iCite
0
iCite
Revised in PubMed
2026-10-31
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ramdial JJhttps://orcid.org/0000-0002-8984-3420
2Chan KHK H
3Sanchez Petitto GG
4Valdez BB
5Andersson BSB Shttps://orcid.org/0000-0003-4761-0220
6Nieto YY

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BusulfanMajor topic
Hematopoietic Stem Cell TransplantationMajor topic
Humans
Acetamides
Myeloablative Agonists
Administration, Intravenous
Transplantation Conditioning

Source PubMed

Download CSV of topics

References18

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112374454
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
Biol Blood Marrow Transplant2002https://conductscience.org/library/papers/12374454PubMed
229501779Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.Biol Blood Marrow Transplant2018https://conductscience.org/library/papers/29501779PubMed
31855615Developmental toxicity of dimethylacetamide by inhalation in the rat.Fundam Appl Toxicol1991https://conductscience.org/library/papers/1855615PubMed
423980086
Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
J Clin Oncol2013https://conductscience.org/library/papers/23980086PubMed
518489993Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.Biol Blood Marrow Transplant2008https://conductscience.org/library/papers/18489993PubMed
618215782High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.Biol Blood Marrow Transplant2008https://conductscience.org/library/papers/18215782PubMed
724065243Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.Blood2013https://conductscience.org/library/papers/24065243PubMed
814005853A phase I study of dimethylacetamide.Cancer Chemother Rep1962https://conductscience.org/library/papers/14005853PubMed
928522110High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.Lancet Haematol2017https://conductscience.org/library/papers/28522110PubMed
103321587Venoocclusive disease of the liver following bone marrow transplantation.Transplantation1987https://conductscience.org/library/papers/3321587PubMed
1130910541Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.Lancet Haematol2019https://conductscience.org/library/papers/30910541PubMed
1215073038Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.Blood2004https://conductscience.org/library/papers/15073038PubMed
138599861Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.Cancer Chemother Pharmacol1996https://conductscience.org/library/papers/8599861PubMed
1424081656Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.Blood2013https://conductscience.org/library/papers/24081656PubMed
1512374451Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.Biol Blood Marrow Transplant2002https://conductscience.org/library/papers/12374451PubMed
1626071868Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.Biol Blood Marrow Transplant2015https://conductscience.org/library/papers/26071868PubMed
1727991894Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.Bone Marrow Transplant2017https://conductscience.org/library/papers/27991894PubMed
186363247Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors.Hepatology1984https://conductscience.org/library/papers/6363247PubMed

Download CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36966213

GET https://conductscience.org/api/papers/v1/36966213/authors